Exhibit 99.1

1 Becton Drive
Franklin Lakes, NJ 07417
www.bd.com

News Release

Contact:

Patricia A. Spinella, Investor Relations — 201-847-5453
Colleen T. White, Corporate Communications — 201-847-5369

BD ANNOUNCES RESULTS FOR FIRST FISCAL QUARTER

The Company raises guidance for full fiscal year

Franklin Lakes, NJ (January 28, 2010) — BD (Becton, Dickinson and Company) (NYSE: BDX) today reported quarterly revenues of $1.917 billion for the first fiscal quarter ended December 31, 2009, representing an increase of 12 percent from the prior-year period, or 9 percent on a foreign currency-neutral basis.

“We are pleased with our solid start to fiscal 2010. Our BD Medical and BD Diagnostics segments led our revenue growth, aided by flu-related sales,” said Edward J. Ludwig, Chairman and Chief Executive Officer. “Our revenue growth, good operating performance and a stabilizing Biosciences business this quarter give us the confidence to raise guidance for fiscal 2010.”

Diluted earnings per share from continuing operations for the quarter were $1.30, an increase of 4 percent over diluted earnings per share from continuing operations of $1.25 for the first quarter of

2009. On a foreign currency-neutral basis, diluted earnings per share from continuing operations for the first quarter of fiscal 2010 increased 11 percent.

Segment Results

In the BD Medical segment, worldwide revenues for the quarter were $1.019 billion, representing an increase of 16 percent from the prior-year period, or 13 percent on a foreign currency-neutral basis. Strong sales of Medical Surgical Systems and Pharmaceutical Systems products, including about 7 percentage points from flu-related products, as well as Diabetes Care products contributed to revenue growth.

In the BD Diagnostics segment, worldwide revenues for the quarter were $595 million, representing an increase of 10 percent from the prior-year period, or 8 percent on a foreign currency-neutral basis. Sales of safety-engineered devices and infectious disease testing systems, including about 2 percentage points from flu-related products, contributed to revenue growth.

In the BD Biosciences segment, worldwide revenues of $303 million for the quarter were flat compared with the prior-year period. Revenues increased less than 1 percent on a foreign currency-neutral basis. Demand for clinical and research instruments, as expected, continues to be impacted by capital funding constraints.

Geographic Results

First quarter revenues in the U.S. were $873 million, representing an increase of 10 percent from the prior-year period. Revenues outside the U.S. were $1.044 billion, representing an increase of 13 percent from the prior-year period, or 8.5 percent on a foreign currency-neutral basis.

Fiscal 2010 Outlook

We expect reported revenues for the full fiscal year 2010 to increase approximately 7 percent, or 6 percent on a foreign currency-neutral basis, compared with our prior guidance of 6 percent, or 5 percent on a foreign currency-neutral basis.

We also expect diluted earnings per share from continuing operations for the full fiscal year 2010 to increase approximately 2 to 4 percent, to $5.05 to $5.15, over adjusted diluted earnings per share from continuing operations, excluding specified items, of $4.95 for the fiscal year 2009, or 8 to 10 percent on a foreign currency-neutral basis. Our prior guidance was an increase of 1 to 3 percent, or 7 to 9 percent on a foreign currency-neutral basis.

Conference Call Information

A conference call regarding BD’s first quarter results and its expectations for the full fiscal year will be broadcast live on BD’s website, www.bd.com/investors, along with related slides, at 10:00 a.m. (ET) Thursday, January 28, 2010. The conference call will be available for replay on BD’s website, www.bd.com/investors, or at 1-800-642-1687 (domestic) and 1-706-645-9291 (international) through the close of business on February 4, 2010, access code 49382392.

Non-GAAP Financial Measures

This news release contains certain non-GAAP financial measures. A reconciliation of these to the comparable GAAP measures is included in the attached financial tables.

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people’s health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD’s capabilities are instrumental in combating many of the world’s most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

***

This press release, including the section entitled “Fiscal 2010 Outlook for Full Year,” contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD’s performance, including future revenues, earnings per share and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, a number of factors could cause actual results to vary materially from any forward-looking statement. For instance, various healthcare reform proposals, if enacted, would impose an excise tax applicable to medical device manufacturers, including BD. Other factors include, but are not limited to: adverse changes in regional, national or foreign economic conditions, including any impact that may result from the current global economic downturn on our ability to access credit markets and finance our operations, the demand for our products and services, or our suppliers’ ability to provide products needed for our operations; changes in interest or foreign currency exchange rates, particularly in light of increased volatility in currency exchange rates; changes in government pricing and reimbursement policies or other healthcare cost containment reforms; competitive factors; pricing and market share pressures; difficulties inherent in product development and delays in product introductions; increases in energy costs and their effect on, among other things, the cost of producing BD’s products; fluctuations in costs and availability of raw materials and in BD’s ability to maintain favorable supplier arrangements and relationships; uncertainties of litigation (as described in BD’s filings with the Securities and Exchange Commission); the effects of potential pandemic diseases; our ability to successfully integrate any businesses we acquire; and issuance of new or revised accounting standards, as well as other factors discussed in BD’s filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per share data)

		Three Months Ended December 31,
		2009				2008				% Change
REVENUES		$	1,916,774			$	1,717,919				11.6
Cost of products sold			919,542				796,274				15.5
Selling and administrative			450,928				406,019				11.1
Research and development			100,284				97,314				3.1
TOTAL OPERATING COSTS AND EXPENSES			1,470,754				1,299,607				13.2
OPERATING INCOME			446,020				418,312				6.6
Interest income			8,789				1,651			NM
Interest expense			(12,987	)			(7,824	)			66.0
Other (expense) income, net			(2,354	)			9,411			NM
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES			439,468				421,550				4.3
Income tax provision			123,490				112,131				10.1
INCOME FROM CONTINUING OPERATIONS			315,978				309,419				2.1
INCOME FROM DISCONTINUED OPERATIONS NET OF INCOME TAX PROVISION OF $152 AND $854, RESPECTIVELY			398				2,649			NM
NET INCOME		$	316,376			$	312,068				1.4
EARNINGS PER SHARE
Basic:
Income from continuing operations		$	1.33			$	1.28				3.9
Income from discontinued operations		$	—			$	0.01			NM
Net income		$	1.33			$	1.29				3.1
Diluted:
Income from continuing operations		$	1.30			$	1.25				4.0
Income from discontinued operations		$	—			$	0.01			NM
Net income		$	1.30			$	1.26				3.2
AVERAGE SHARES OUTSTANDING
Basic			237,360				242,397
Diluted			242,965				248,311

NM — Not Meaningful

Page 1

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY SEGMENT AND GEOGRAPHIC AREA
(Unaudited; Amounts in thousands)

		Three Months Ended December 31,
		2009				2008				% Change
BD MEDICAL
United States		$	452,385			$	394,161				14.8
International			566,243				481,029				17.7
TOTAL		$	1,018,628			$	875,190				16.4
BD DIAGNOSTICS
United States		$	310,205			$	287,568				7.9
International			285,269				252,623				12.9
TOTAL		$	595,474			$	540,191				10.2
BD BIOSCIENCES
United States		$	110,636			$	113,751				(2.7	)
International			192,036				188,787				1.7
TOTAL		$	302,672			$	302,538				—
TOTAL REVENUES
United States		$	873,226			$	795,480				9.8
International			1,043,548				922,439				13.1
TOTAL		$	1,916,774			$	1,717,919				11.6

Page 2

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended December 31,
(Unaudited; Amounts in thousands)

		United States
		2009				2008				%Change
BD MEDICAL
Medical Surgical Systems		$	286,535			$	256,255				11.8
Diabetes Care			96,564				88,465				9.2
Pharmaceutical Systems			62,021				42,652				45.4
Ophthalmic Systems			7,265				6,789				7.0
TOTAL		$	452,385			$	394,161				14.8
BD DIAGNOSTICS
Preanalytical Systems		$	156,236			$	149,230				4.7
Diagnostic Systems			153,969				138,338				11.3
TOTAL		$	310,205			$	287,568				7.9
BD BIOSCIENCES
Cell Analysis		$	77,604			$	77,379				0.3
Discovery Labware			33,032				36,372				(9.2	)
TOTAL		$	110,636			$	113,751				(2.7	)
TOTAL UNITED STATES		$	873,226			$	795,480				9.8

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended December 31, (continued)
(Unaudited; Amounts in thousands)

		International
										% Change
		2009				2008				Reported				FXN				FX Impact
BD MEDICAL
Medical Surgical Systems		$	273,491			$	224,246				22.0				15.3				6.7
Diabetes Care			104,957				91,541				14.7				7.7				7.0
Pharmaceutical Systems			173,953				152,129				14.3				7.3				7.0
Ophthalmic Systems			13,842				13,113				5.6				2.8				2.8
TOTAL		$	566,243			$	481,029				17.7				11.0				6.7
BD DIAGNOSTICS
Preanalytical Systems		$	143,930			$	128,924				11.6				6.8				4.8
Diagnostic Systems			141,339				123,699				14.3				10.0				4.3
TOTAL		$	285,269			$	252,623				12.9				8.3				4.6
BD BIOSCIENCES
Cell Analysis		$	153,731			$	152,142				1.0				1.9				(0.9	)
Discovery Labware			38,305				36,645				4.5				4.9				(0.4	)
TOTAL		$	192,036			$	188,787				1.7				2.5				(0.8	)
TOTAL INTERNATIONAL		$	1,043,548			$	922,439				13.1				8.5				4.6

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended December 31, (continued)
(Unaudited; Amounts in thousands)

		Total
										% Change
		2009				2008				Reported				FXN				FX Impact
BD MEDICAL
Medical Surgical Systems		$	560,026			$	480,501				16.6				13.4				3.2
Diabetes Care			201,521				180,006				12.0				8.4				3.6
Pharmaceutical Systems			235,974				194,781				21.1				15.6				5.5
Ophthalmic Systems			21,107				19,902				6.1				4.3				1.8
TOTAL		$	1,018,628			$	875,190				16.4				12.7				3.7
BD DIAGNOSTICS
Preanalytical Systems		$	300,166			$	278,154				7.9				5.7				2.2
Diagnostic Systems			295,308				262,037				12.7				10.7				2.0
TOTAL		$	595,474			$	540,191				10.2				8.1				2.1
BD BIOSCIENCES
Cell Analysis		$	231,335			$	229,521				0.8				1.3				(0.5	)
Discovery Labware			71,337				73,017				(2.3	)			(2.1	)			(0.2	)
TOTAL		$	302,672			$	302,538				—				0.5				(0.5	)
TOTAL REVENUES		$	1,916,774			$	1,717,919				11.6				9.1				2.5

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
SAFETY REVENUES
(Unaudited; Amounts in thousands)

		Three Months Ended December 31,
										% Change
		2009				2008				Reported				FXN				FX Impact
TOTAL SAFETY REVENUES
United States		$	298,258			$	268,969				10.9				10.9				—
International			156,015				134,080				16.4				10.5				5.9
TOTAL		$	454,273			$	403,049				12.7				10.8				1.9
BY SEGMENT
BD Medical		$	228,503			$	192,751				18.5				16.4				2.1
BD Diagnostics			225,770				210,298				7.4				5.5				1.9
TOTAL		$	454,273			$	403,049				12.7				10.8				1.9